Sai Parenterals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for SAIPARENT, Sai Parenterals Ltd.

Search Inside the pdf :

Sai Parenterals Ltd.

24 Mar 2026

SAI PARENTERAL'S LTD

Sai Parenterals Ltd.

Hem Securities

Company is a diversified pharmaceutical formulations company with capabilities in research, development and manufacturing. Company is in the business of (i) Branded Generic Formulations and (ii) Contract Development and Manufacturing Organisation (CDMO) products and services for the domestic and international markets. Company's portfolio includes formulation products across various therapeutic areas like cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics,...

Deven Choksey released a IPO Note report for Sai Parenterals Ltd. on 23 Mar, 2026.

Sai Parenterals Ltd.

23 Mar 2026

SAI PARENTERALS LTD.

Sai Parenterals Ltd.

Ventura

IPO NOTE

Deven Choksey released a IPO Note report for Sai Parenterals Ltd. on 23 Mar, 2026.

Sai Parenterals Ltd.

23 Mar 2026

IPO Note

Sai Parenterals Ltd.

Deven Choksey

The company's historical financials and overall business model offer limited predictive value as the company is at an inflection point, transitioning into an export-oriented entity.

Deven Choksey released a IPO Note report for Sai Parenterals Ltd. on 23 Mar, 2026.

Sai Parenterals Ltd.

20 Mar 2026

SAI Parenteral's Ltd: IPO

Sai Parenterals Ltd.

ICICI Direct

About the Company: Sai Parenteral's is a Hyderabad-based global formulations company engaged in developing and manufacturing of formulations across multiple therapeutic areas and dosage forms. The company owns installed capacities for injectables, tablets, capsules, liquid orals and ointments, with a total of 5 manufacturing facilities in...

Deven Choksey released a IPO Note report for Sai Parenterals Ltd. on 23 Mar, 2026.

Sai Parenterals Ltd.

20 Mar 2026

Sai Parenteral's Ltd IPO Note

Sai Parenterals Ltd.

SBI Securities

Sai Parenteral's Ltd. (SPL) is a diversified pharmaceutical formulations company, engaged in the business of (a) Branded Generic Formulations, and (b) Contract Development and Manufacturing Organisation (CDMO) products & services for the domestic and international markets. The company's portfolio includes formulation products, covering both high-value and high-volume categories across therapeutic areas like cardiovascular, neuropsychiatry, anti-diabetic, etc., with offerings across...

Deven Choksey released a IPO Note report for Sai Parenterals Ltd. on 23 Mar, 2026.